Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, Duffin KL, Taskinen MR, Ruotolo G. Wilson JM, et al. Among authors: ruotolo g. Diabetes Obes Metab. 2020 Dec;22(12):2451-2459. doi: 10.1111/dom.14174. Epub 2020 Sep 15. Diabetes Obes Metab. 2020. PMID: 33462955 Free PMC article. Clinical Trial.
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, Robins DA, Haupt A, Duffin KL, Ruotolo G. Wilson JM, et al. Among authors: ruotolo g. Diabetes Obes Metab. 2022 Jan;24(1):148-153. doi: 10.1111/dom.14553. Epub 2021 Oct 11. Diabetes Obes Metab. 2022. PMID: 34542221 Free PMC article. Clinical Trial.
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE. Menon V, et al. Among authors: ruotolo g. J Am Heart Assoc. 2020 Jan 7;9(1):e014328. doi: 10.1161/JAHA.119.014328. Epub 2019 Dec 19. J Am Heart Assoc. 2020. PMID: 31852422 Free PMC article. Clinical Trial.
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
Menon V, Kumar A, Patel DR, St John J, Riesmeyer J, Weerakkody G, Ruotolo G, Wolski KE, McErlean E, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE. Menon V, et al. Among authors: ruotolo g. BMJ Open Diabetes Res Care. 2020 Mar;8(1):e000943. doi: 10.1136/bmjdrc-2019-000943. BMJ Open Diabetes Res Care. 2020. PMID: 32179516 Free PMC article. Clinical Trial.
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.
Kumar A, Patel DR, Wolski KE, Lincoff AM, Kashyap SR, Ruotolo G, McErlean E, Weerakkody G, Riesmeyer JS, Nicholls SJ, Nissen SE, Menon V. Kumar A, et al. Among authors: ruotolo g. Diab Vasc Dis Res. 2019 Mar;16(2):171-177. doi: 10.1177/1479164119827604. Diab Vasc Dis Res. 2019. PMID: 31014095 Free article.
146 results